Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Description: Pemphigus vulgaris is an autoimmune, chronic and recurrent blistering disease with unknown etiology that affects mucosa and skin of patients with significant morbidity and mortality.

The treatment back-bone is based on prednisolone administration. There are controversies on the opportunity of adding immunosuppressive drugs. For some, they are just corticosteroid sparing drugs. For others, they are disease modifying drugs.

The purpose of this trial is to compare efficacy and safety of azathioprine vs. placebo in new cases of pemphigus vulgaris treated with prednisolone.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Treatments: Azathioprine; Prednisone

Criteria

Inclusion Criteria:

• Lesions clinically consistent with pemphigus vulgaris

• Diagnosis confirmed by histology in terms of acantholysis within past month

• Positive DIF

Exclusion Criteria:

• Any nursing or pregnant woman

• Any history of chronic diseases including liver disease, Chronic Renal Failure, Chronic Heart Failure or Ischemic Heart Disease

• Present diagnosis of hepatitis confirmed by serology or elevated hepatic enzymes;

• Clinically significant concurrent medical disease or laboratory abnormalities evidenced by one or more of the following:

• Hepatobiliary AST or ALT ≥ 1.5 × upper limit of normal (ULN);alkaline phosphatase ≥ 1.5 × ULN; or, total bilirubin > 90% of the ULN;

• Renal serum creatinine > 1.5 mg/dL; or, significant proteinuria > 2+ on urinary dip test;

• Hematologic hemoglobin < 11 mg/dL; leukocytes < 3.5 × 109/L; neutrophils < 1.5 × 109/L; or, platelets < 100 × 109/L; Presence of anemia, leukopenia or thrombocytopenia

• Any sign of patient's non-compliance

• Known hypersensitivity to study drugs, prednisone or azathioprine

• Participating in another clinical trial at the time of screening and enrollment